FY2023 · ended Dec 31, 2023 · Revenue $0, -100.0% YoY · Filed Mar 18, 2025
XBiotech Inc. (XBIT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$40.2 million.
Revenue
$0
-100.0% vs prior year
Net income
$-45.54M
-18.2% vs prior year
Operating cash flow (TTM)
$-40.70M
-62.2% vs year-ago TTM
Free cash flow (TTM)
$-40.84M
-59.1% vs year-ago TTM
EPS
$-1.49
-18.3% vs prior year
Dividend per share
None
Shares outstanding
30.49M
+0.0% vs prior year
Net cash
—
Operating margin
-860.1%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1626878
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $4.0M | $18.4M |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M |
| Diluted EPS | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 |
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M |
| Stockholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M |
| Cash and investments | $125.6M | $172.7M | $200.0M | $217.5M | $237.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 26, 2026 | Oct 23, 2026 |
| ARS | Annual report to shareholders | Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 407 XBiotech Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.